A recent article published in Value in Health outlines the Institute for Clinical and Economic Review’s (ICER) methodology, as well as its impact in the drug pricing landscape.
The organization’s efforts, Tufts Medical Center’s Peter Neumann writes, marks a move toward a more evidence-based model for drug valuation and patient access.
“[ICER] is a private, nonprofit group that disseminates information rather than possessing regulatory or reimbursement authority … ,” Neumann writes. “Its information provides one input that payers use to inform a complex decision-making process. Even as this research moves ahead, we should recognize that the value frameworks are already in prime time.”
To read the article, click here. (Paid subscription required)
